2-(1-adamantyl)-N-pentylethylamine | 379265-11-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-(1-adamantyl)-N-pentylethylamine
• 英文别名: N-[2-(1-adamantyl)ethyl]pentan-1-amine
• CAS: 379265-11-9
• 化学式: C₁₇H₃₁N
• 分子量: 249.44
• InChiKey: QVHCDIXOASJMAN-UHFFFAOYSA-N

物化性质

• 沸点：
  316.1±10.0 °C(Predicted)
• 密度：
  0.947±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-[3-(4-pyridyl)propylaminocarbonyl]imidazole 、 2-(1-adamantyl)-N-pentylethylamine 反应 1.0h， 生成 SA13353
  参考文献：
  名称：

  Synthesis and pharmacological evaluation of 1,1,3-substituted urea derivatives as potent TNF-α production inhibitors

  摘要：

  A three substituted urea derivative, SA13353 (compound 1a), exhibited potent inhibitory activity against lipopolysaccharide (LPS)-induced TNF-alpha production. We focused on the 1,1-substituted moiety (R(1) and R(2)) of SA13353 and investigated substituent effects of this moiety on LPS-induced TNF-alpha production by oral administration in rats. The synthesis of the urea derivatives was performed rapidly in a one-pot manner using a manual synthesizer. Several compounds containing hydrophobic substituents at this moiety showed more potent inhibitory activities than SA13353. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.06.037
• 作为产物：
  描述：

  1-<2-(mesyloxy)ethyl>adamantane 、 1-氨基戊烷 在 potassium carbonate 、 sodium iodide 作用下， 以 乙醇 为溶剂， 反应 17.0h， 生成 2-(1-adamantyl)-N-pentylethylamine
  参考文献：
  名称：

  Synthesis and pharmacological evaluation of 1,1,3-substituted urea derivatives as potent TNF-α production inhibitors

  摘要：

  A three substituted urea derivative, SA13353 (compound 1a), exhibited potent inhibitory activity against lipopolysaccharide (LPS)-induced TNF-alpha production. We focused on the 1,1-substituted moiety (R(1) and R(2)) of SA13353 and investigated substituent effects of this moiety on LPS-induced TNF-alpha production by oral administration in rats. The synthesis of the urea derivatives was performed rapidly in a one-pot manner using a manual synthesizer. Several compounds containing hydrophobic substituents at this moiety showed more potent inhibitory activities than SA13353. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.06.037

文献信息

• Angiogenesis inhibitor
  申请人：Matsuoka Hidehito

  公开号：US20050014800A1

  公开（公告）日：2005-01-20

  An object of the present invention is to find new pharmacological actions of urea compounds having structure represented by the general formula [1]. The urea compounds having the structure represented by the general formula [1] have excellent angiogenesis inhibitory actions. [wherein “A” is —(NR 4 )—, —(CR 5 R 6 )— or —O—, “B” is alkylene or alkenylene, R 1 , R 2 , R 4 , R 5 and R 6 are hydrogen, alkyl, alkenyl, adamantylalkyl or the like, R 3 is aryl or an unsaturated heterocycle, and X is oxygen or sulfur.]

  本发明的目的是寻找具有一般式[1]所代表的结构的尿素化合物的新的药理作用。具有一般式[1]所代表的结构的尿素化合物具有出色的血管生成抑制作用。[其中“A”是-（NR4）-，-（CR5R6）-或-O-，“B”是烷基或烯基，R1，R2，R4，R5和R6为氢，烷基，烯基，金刚烷基或类似物，R3为芳香族或不饱和杂环，X为氧或硫。]
• TNF-alpha production inhibitors
  申请人：Ban Masakazu

  公开号：US20060241155A1

  公开（公告）日：2006-10-26

  A purpose of the present invention is to provide TNF-α production inhibitors being useful as therapeutic agents for autoimmune diseases such as rheumatoid arthritis. Novel compounds having the structure represented by the general formula [1] or salts thereof according to the present invention have excellent TNF-α production inhibitory activities, wherein A is —(NR 4 )—, —(CR 5 R 6 )— or —O—, B is alkylene or alkenylene, R 1 , R 2 , R 4 , R 5 and R 6 are hydrogen, alkyl, alkenyl, adamantyl or the like, R 3 is aryl or an unsaturated heterocycle, and X is oxygen or sulfer respectively.

  本发明的目的是提供一种可用作治疗自身免疫疾病如类风湿性关节炎的治疗剂的TNF-α产生抑制剂。根据本发明，具有由一般式[1]表示的结构或其盐的新化合物具有出色的TNF-α产生抑制活性，其中A是-（NR4）-，-（CR5R6）-或-O-，B是烷基或烯基，R1、R2、R4、R5和R6是氢、烷基、烯基、金刚烷基或类似物，R3是芳基或不饱和杂环，X分别是氧或硫。
• Angiogenesis inhibitors
  申请人：Matsuoka Hidehito

  公开号：US20080161270A1

  公开（公告）日：2008-07-03

  An object of the present invention is to find new pharmacological actions of urea compounds having structure represented by the general formula [1]. The urea compounds having the structure represented by the general formula [1] have excellent angiogenesis inhibitory actions. [wherein “A” is —(NR 4 )—, —(CR 5 R 6 )— or —O—, “B” is alkylene or alkenylene, R 1 , R 2 , R 4 , R 5 and R 6 are hydrogen, alkyl, alkenyl, adamantylalkyl or the like, R 3 is aryl or an unsaturated heterocycle, and X is oxygen or sulfur.]

  本发明的目的是找到具有一般式[1]所代表的结构的尿素化合物的新药理作用。具有一般式[1]所代表的结构的尿素化合物具有出色的抑制血管生成作用。[其中“A”为—(NR4)—，—(CR5R6)—或—O—，“B”为烷基或烯基，R1、R2、R4、R5和R6为氢、烷基、烯基、脱氢壳聚糖烷基或类似物，R3为芳基或不饱和杂环，X为氧或硫。]
• ANGIOGENESIS INHIBITOR
  申请人：SANTEN PHARMACEUTICAL CO., LTD.

  公开号：EP1457205A1

  公开（公告）日：2004-09-15

  An object of the present invention is to find new pharmacological actions of urea compounds having structure represented by the general formula [1]. The urea compounds having the structure represented by the general formula [1] have excellent angiogenesis inhibitory actions. [wherein "A" is -(NR4)-, -(CR5R6)- or -O-, "B" is alkylene or alkenylene, R1, R2, R4, R5 and R6 are hydrogen, alkyl, alkenyl, adamantylalkyl or the like, R3 is aryl or an unsaturated heterocycle, and X is oxygen or sulfur.]

  本发明的目的是寻找具有通式[1]结构的脲化合物的新药理作用。具有通式[1]结构的脲化合物具有良好的血管生成抑制作用。 [其中 "A "是-(NR4)-、-(CR5R6)-或-O-，"B "是亚烷基或烯基，R1、R2、R4、R5 和 R6 是氢、烷基、烯基、金刚烷基或类似物，R3 是芳基或不饱和杂环，X 是氧或硫。］
• TNF-Alpha production inhibitors for the treatment of autoimmune diseases
  申请人：SANTEN PHARMACEUTICAL CO., LTD.

  公开号：EP1561749B1

  公开（公告）日：2007-03-28